Cancer: Annual deaths compared to new cases in 2004, for 16 types of cancer and 4 World Bank income groups

The following table compares the annual deaths from cancer, to the annual incidence of the disease, broken down by cancer type and income group. The data in the table is annual deaths divided by annual incidence, show as a ratio.

For several types of cancer, there is not much difference in the reported ratios, between different income groups. For other types of cancer, the differences are large, and in favor of patients living in higher income countries. Cancer types with the largest disparities by income include the following:

Uncategorized
2

USTR’s Request for Comments on ACTA

USTR has issued a request for comments on ACTA. The deadline for submissions is February 15, 2011. The notice gives very little guidance regarding the issues the USTR would like addressed in the comments.


[Billing Code 3190-W1-P]

Office of the United States Trade Representative

Anti-Counterfeiting Trade Agreement: Request for Comments from the Public

Agency: Office of the United States Trade Representative

Action: Request for written submissions from the public

Continue Reading

Uncategorized

Notes from meeting with USTR on the TPP IPR chapter

Today USTR provided some additional insight into negotiations of a regional, Asia-Pacific trade agreement, known as the Trans-Pacific Partnership (TPP) Agreement. The USTR web page on the TPP negotiations is http://www.ustr.gov/tpp. At present, the TPP negotiators include Australia, Brunei Darussalam, Chile, New Zealand, Peru, Singapore and Vietnam. Japan and Canada have expressed interest in joining the negotiations, and USTR clearly would like to design an agreement that will be open to other countries. Our discussions focused on the intellectual property chapter in the agreement. Continue Reading

Uncategorized

Development Agenda committee mandates WIPO to examine Bolivia, Barbados, Suriname and Bangladesh prize proposals

On Friday, 26 November 2010, the 6th session of the WIPO Committee on Development Agenda and Intellectual Property approved a project entitled “Project on Open Collaborative Projects and IP-Based Models”. As mentioned in KEI’s previous posting on this subject, this project endeavors to implement Recommendation 36 of the Development Agenda which states:

Continue Reading

Uncategorized

NIH funded research involving trastuzumab (marketed by Roche under the trade name Herceptin)

13 December 2010

Drugs@FDA
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998

What is Herceptin? How does it work?

Continue Reading

Uncategorized

Statements by KEI and others on NIH rejection of Fabrazyme March-In Request

For background on the Fabrazyme case, see: http://www.keionline.org/fabrazyme

The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.

Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)

Continue Reading